7 months ago
1
Danish pharma large Novo Nordisk connected Friday (December 12, 2025) launched its blockbuster benignant 2 diabetes attraction injection Ozempic, globally fashionable for its weight-loss benefits.
Ozempic is present disposable successful India arsenic 0.25 mg, 0.5 mg and 1 mg successful 'FlexTouch Pen' - an easy-to-use, once-weekly pen device, astatine a starting outgo of Rs 2,200 per week. Each pen has 4 once-weekly doses, the institution announced successful New Delhi.
A diligent prescribed Ozempic injection would commencement with a 0.25 mg dose for 4 weeks astatine a full outgo of ₹8,800.
Afterwards, arsenic per diagnosis by the doctor, the diligent moves to either the adjacent phase, 'step' of 0.5 mg dose for astatine slightest 4 weeks costing ₹10,170 oregon to the 'stay' signifier of 1 mg dose per week with the monthly outgo pegged astatine ₹11,175, it said.
This is the company's 2nd medicine that has semaglutide arsenic the progressive constituent to beryllium launched successful India aft its weight-loss cause Wegovy.
While Wegovy, launched successful India successful June 2025, is indicated for chronic value management, Novo Nordisk is positioning Ozempic arsenic a attraction of benignant 2 diabetes with value nonaccomplishment benefits, competing with Eli Lily's Mounjaro that was launched successful March this year.
Novo Nordisk India Managing Director Vikrant Shrotriya said done Ozempic, the institution is looking to supply patients with an innovative and accessible therapy for the attraction of benignant 2 diabetes portion besides offering meaningful value absorption and semipermanent bosom and kidney protection.
"We are precise judicious successful presumption of pricing successful India. It truly remains precise competitive, internally and externally arsenic well, to connection astatine a terms similar this," Mr. Shrotriya told PTI erstwhile asked however Ozempic pricing successful India compares with different planetary markets.
"I would accidental that it inactive comes nether the affordability portion of the pricing, which is astatine a scope for countries akin to India." Novo Nordisk is selling Ozempic purely arsenic a attraction for benignant 2 diabetes successful India, helium added.
"We applied for benignant 2 diabetes. We got (approval from the cause regulator successful India) for it," helium noted.
In presumption of Ozempic organisation successful India, Mr. Shrotriya said Novo Nordisk is going unsocial to marque it disposable crossed the country.
The company's concern with Emcure Pharma volition stay strictly for value nonaccomplishment medicine Poviztra, semaglutide injection 2.4 mg, the 2nd marque of Wegovy successful India, helium added.
Asked astir the marketplace accidental for Ozempic successful India, Mr. Shrotriya said it was hard to estimate, arsenic globally also, predicting it for the medicine has proven to beryllium tough, with request exceeding the supply.
One of the reasons for Ozempic being launched precocious successful India was besides to bash with ensuring uninterrupted supplies, helium said, adding that the injection would beryllium imported from Denmark, wherever it is produced.
"We stay precise agile and precise flexible successful presumption of our proviso concatenation to work India," helium said.
With the patent for injectable semaglutide expiring adjacent year, helium said the institution is prepared for competition, arsenic generic players are expected to participate the marketplace and is assured that its merchandise prime and marque equity volition marque patients take its product.
Ozempic (injectable semaglutide) is indicated arsenic an adjunct to fare and workout for adults surviving with uncontrolled benignant 2 diabetes mellitus (T2DM) erstwhile a week.
Citing World Health Organisation 2023-24 estimates, the institution said India has 101 cardinal (roughly 11.4% of its population) radical surviving with diabetes, making it the 2nd largest diabetes-affected colonisation successful the satellite aft China.
The state besides has 136 cardinal individuals with prediabetes and 254 cardinal radical surviving with generalised obesity, signalling an accelerating wellness situation that requires effective, evidence-based therapies, it added.
